Pfizer Faces Suit Over Recalled Sickle Cell Medicine Oxbryta (1)

Pfizer Inc. and its subsidiary Global Blood Therapeutics Inc. should have known that their now-recalled treatment for sickle cell disease Oxbryta could cause complications and even death, a patient alleged in a new lawsuit.

Plaintiff Tirrell Allen said he experienced a higher rate of vaso-occlusive crisis, a disease complication, after using the medication, according to the complaint filed Thursday in the US District Court for the Northern District of California.

A spokesperson for Pfizer said the company “acted responsibly at all times in the development and testing of Oxbryta and will vigorously defend this suit.”

Sickle cell is a genetic ...